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Systemic virus dissemination is a potential problem during local gene delivery in solid tumours. However, the kinetics and pathways of
the dissemination have not been well characterised during the first 24h after the infusion is started. To this end, we infused adenoviral
vectors for luciferase or enhanced green fluorescence protein into three different tumour models in mice. During and/or after the
infusion, we determined the amount of adenoviruses in the tumour, blood, and liver, and examined the transgene expression in the
liver, lung, blood, and tumour. In addition, we intravenously injected tumour cells expressing luciferase and examined the
biodistribution of these cells in the body. We observed transgene expression in the liver and tumour at 24h after the infusion, but
could not detect transgene expression in the blood and lung. The peak concentration of viral vectors in the plasma occurred during
the intratumoral infusion. At 10min after the infusion, few viral vectors remained in the blood and the ratio of copy numbers of
adenoviruses between liver and tumour was 42 in 80% and X10 in 40% of the mice. Most tumour cells injected intravenously
accumulated in the lung within the first 24h. Taken together, these data indicated that systemic virus dissemination occurred mainly
during the first 10min after the intratumoral infusion was started, and that the dissemination was due to infusion-induced convective
transport of viral vectors into leaky tumour microvessels.
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Gene therapy represents a new paradigm to treat cancer at the
genetic level (Ledley, 1996; Anderson, 1998). Its success relies on
the ability to deliver sufficient genetic materials into target cells.
The most widely used vectors for gene delivery are genetically
engineered viruses, because they, in the long-term evolution of
nature, are equipped with specific machineries that facilitate DNA
transport into the nucleus of cells (Baranowski et al, 2001).
However, a main drawback of viral vectors is the toxicity caused by
undesirable acute immune response to viral proteins (Brown and
Lillicrap, 2002; Bowers et al, 2003; Chen et al, 2003; Jooss and
Chirmule, 2003; Lowenstein, 2003). Moreover, proteins from
transgene expression may also exert adverse effects on normal
cells either directly or indirectly through conversion of prodrugs to
cytotoxic agents (Freeman et al, 1993; Rosenfeld et al, 1995;
Alvarez and Curiel, 1997; Pope et al, 1997; Chada et al, 2003). Both
toxicity and efficacy of gene therapy increase with the dose of
treatment. Therefore, the goal of research in gene delivery is to
improve the efficacy/toxicity ratio (Crystal, 1995; Alemany et al,
2000a).
The improvement can be achieved through increasing the
specificity of either vector delivery or transgene expression in
tumour cells. One way to increase the delivery specificity is to
physicochemically or genetically modify viral surface proteins so
that the vectors will target specific biomarkers in tumours
(Douglas et al, 1996; Hall et al, 1997). However, this approach
has its limitations because such biomarkers may exist in normal
tissues and distribute heterogeneously in tumours. To reduce
transgene expression in normal tissues, unique promoters have
been integrated into viral vectors. These promoters can
be activated only by specific stimuli in tumours that are either
endogenous or applied externally (Vaupel et al, 1989; Gossen
and Bujard, 1992; Garver et al, 1994; Harris et al, 1994; Hallahan
et al, 1995; Kumagai et al, 1996; Jaggar et al, 1997; Jenster et al,
1997; Blackburn et al, 1998; Chung et al, 1999; Abdul-Ghani et al,
2000; Huang et al, 2000; Koshikawa et al, 2000; Pollock et al, 2000;
Spitz et al, 2000). However, the control of transgene expression will
not reduce the acute toxicity in normal tissues caused by viral
proteins.
Intratumoral infusion is another strategy for improving the
efficacy/toxicity ratio in viral gene therapy. It has been widely used
in cancer clinical trials. Researchers often assume that viral vectors
and transgene expression are confined to solid tumours after the
infusion, thereby causing minimal toxicity in normal tissues (Lu
et al, 1999; Paielli et al, 2000). On the other hand, researchers in
some studies have observed that transgene expression in normal
tissues can be as strong as that in tumours (Toloza et al, 1996;
Bramson et al, 1997; Nasu et al, 1999; Tjuvajev et al, 1999; Lohr
et al, 2001; Wang et al, 2003), that adenoviral vectors are present in
systemic circulation of patients in clinical trials (DeWeese et al,
2001; Nemunaitis et al, 2001), and that some animals die within a
short period after intratumoral infusion (Toloza et al, 1996;
Tjuvajev et al, 1999). These observations indicate that viral vectors
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scan escape from tumours during and/or after intratumoral
infusion. Thus, the improvement in efficacy/toxicity ratio via the
intratumoral infusion is likely to be far from optimal.
Although virus dissemination has been observed in preclinical
and clinical studies, its kinetics and pathways are still controver-
sial. Therefore, we characterised the biodistributions of adenoviral
vectors and transgene expression in the tumour, liver, blood, and
lung at different time points after the infusion was started. We
observed that the systemic virus dissemination occurred mainly
within the first 10min. The amount of viruses disseminated into
the liver could be one order of magnitude higher than that retained
in the tumour, and the mechanism of dissemination was the
infusion-induced convective transport of viral vectors into leaky
tumour microvessels.
MATERIALS AND METHODS
Adenoviral vectors
The Ad5-based recombinant system was used to produce the
nonreplicating adenoviruses: AdCMVEGFP and AdCMVLuc en-
coding enhanced green fluorescence protein (EGFP) and luciferase,
respectively. The cDNA for EGFP or luciferase was inserted into
the E1 region of the adenovirus and the transgene expression was
driven by the cytomegalovirus (CMV) promoter. Adenoviruses
were propagated in 293 cells (ATCC, Manassas, VA, USA),
harvested at 48h after infection, and purified by the method of
cesium chloride gradient centrifugation according to a standard
protocol (Graham and Prevec, 1995). The viral vectors were stored
in 10% glycerol at  821C.
Tumour cell lines
Three tumour cell lines (4T1, B16.F10, and IMR-23) were used
in the study. 4T1 is a murine mammary carcinoma; B16.F10 is a
metastatic subline of B16 murine melanoma; IMR-23 is a human
neuroblastoma. All tumour cells were cultured in DMEM
supplemented with 10% newborn bovine serum (Hyclone,
Logan, UT, USA) and 1% penicillin/streptomycin (Gibco/Life
Technologies, Grand Island, NY, USA) at 371C with 5% CO2
and 95% air. For tumour implantation in mice, the cells were
removed from culture flasks with 0.25% trypsin/EDTA and rinsed
twice in PBS.
Animals
Female Balb/c and C57BL/6 mice, 4–6 weeks old, were ordered
from Charles River Laboratory (Wilmington, MA, USA) for the
implantation of 4T1 and B16.F10 tumours, respectively. Female
Balb/c nude mice at the same age as Balb/c mice were ordered from
the National Cancer Institute (Bethesda, MD, USA) for the
implantation of IMR-23 tumour. For tumour cell implantation,
mice were first anesthetised with an intraperitoneal injection
(0.15ml) of a mixture of ketamine and xylazine (80mg ketamine
and 10mg xylazine per kg body weight). Then, one million tumour
cells in 50ml PBS were injected subcutaneously into the right hind
limb of mice. After implantation, the mice were placed on a warm
pad until they woke up. All subcutaneous tumours were ready for
experiments when they reached 5–8mm in diameter. After
experiments, fully anaesthetised mice were killed with cervical
dislocation. The use of animals and all experimental procedures
involving animals in this study had been approved by the Duke
University Institutional Animal Care and Use Committee. These
procedures were also consistent with the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR) Guidelines
(UKCCCR, 1998).
Intratumoral infusion
Mice were anesthetised with an intraperitoneal injection (0.15ml)
of a mixture of ketamine and xylazine (80mg ketamine and
10mg xylazine per kg body weight). The tip of a 30-gauge
needle was carefully placed near the centre of tumours by
controlling the depth of needle insertion relative to the tumour
size measured by a caliper. Virus suspension was infused
into tumours via the needle mounted on a syringe pump
(model 22, Harvard Apparatus Co., Cambridge, MA, USA). The
volume of infusion was fixed at 50ml although the dose of viruses
varied with experiments as indicated below. The infusion rate
was chosen to be 1mls
 1 based on a preliminary study in which we
infused 50ml of a solution of Evans blue dye or a suspension of an
adenoviral vector for LacZ, AdCMVLacZ, into 4T1 tumours
and observed that the distribution volume of Evans blue or
b-galactosidase in tumours was the highest when the infusion rate
was 1mls
 1.
Luciferase and EGFP expression in different organs/tissues
At 24h after intratumoral infusion of AdCMVLuc or AdCMVEGFP
(2.0 10
8 plaque forming units (pfu)), mice were anesthetised
again with the same method as described above and transgene
expression in tumours was examined. For luciferase analysis, 50ml
of aqueous D-luciferin solution was injected intraperitoneally into
the mice placed on a warm pad at 20min before the examination of
bioluminescence in the body. The bioluminescence was recorded
by the In Vivo Imaging System (IVIS) (Xenogen Corp., Alameda,
CA, USA), with an exposure time of 30s (Wang et al, 2003) and the
bioluminescence intensity was represented by pseudo-colours as
indicated by a colour bar. The final images were generated by
superimposing the pseudo-colour bioluminescence images on the
reference images. For EGFP analysis, tissue samples from the
blood, lung, liver, and tumour were harvested. Except the blood,
tissue samples were sectioned into thin slices (300mm thick), using
a Vibratome (Model 3000; Technical Products International, St
Louis, MO, USA). Enhanced green fluorescence protein expression
in the blood and sliced tissues was examined under a confocal
laser-scanning microscope (LSM 510, Carl Zeiss, Thornwood, NY,
USA).
In a separate experiment, we injected 10
6 luciferase-expressing
4T1 cells in a 100-ml suspension into the tail vein of Balb/c mice
anesthetised with the same method as described above. At both
10min and 24h after the cell injection, luciferase expression in the
body was examined using the same method as described above.
Qualitative analysis of adenoviruses in the blood
At predetermined time points (25s, 50s, 5min, 10min, 2, and 24h)
after starting the infusion of AdCMVEGFP (3.0 10
8pfu) into 4T1
tumours, blood samples (approximately 20ml in each sample) from
anesthetised mice were collected through the orbital sinus with
a heparinised capillary, stored at room temperature for 10min,
and centrifuged at 10000g for 3min to separate the plasma from
blood cells. The plasma and cell suspension were then exposed
to four cycles of thawing (371C) and freezing ( 1961C in liquid
nitrogen) treatment. In all, 1ml of plasma solution or suspension
of lysed blood cells was added into 96-well plates with 70–80%
confluent 293 cells. After 24h, EGFP expression in these cells was
examined under a fluorescence microscope (Axiovert 100, Carl
Zeiss).
Quantitative analysis of adenovirus dissemination in liver
and tumours
At 10min after the infusion of AdCMVEGFP (3.0 10
8pfu) into
4T1 tumors, mice were killed with cervical dislocation and the liver
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sand tumours were immediately harvested, frozen in liquid
nitrogen, and stored at  821C. For viral DNA analysis, the tissue
samples were immersed in liquid nitrogen and ground into fine
tissue powder in a mortar. Viral DNA was isolated from the tissue
powder using a DNeasy Tissue kit (Qiagen, Clarita, CA, USA). The
DNeasy mini column was eluted twice with 200ml of Tris buffer
(10mM,p H ¼8.5) to obtain viral DNA solution, in which Ad E4
copy number was measured with the Smart Cycler System
(Cepheid, Sunnyvale, CA, USA). In the real-time PCR analysis,
the primers and probes were purchased from Sigma-Genosis
(Woodlands, TX USA). The forward primer sequence for Ad E4
region was: 50-TGACACGCATACTCGGAGCTA-30: 34885–34905;
the reverse primer sequence was: 50-TTTGAGCAGCACCTTG
CATT-30: 34977–34958; the fluorogenic probe sequence was:
[DFAM]CGCCGCCCATGCAACAAGCTT[DBH1]: 34930–34951
(Adachi et al, 2001). Each PCR reaction was performed in
duplicate in a 25-ml reaction mixture containing 0.15mlo f
AmpliTaq Gold DNA polymerase (5Uml
 1) (Applied Biosystems,
Foster City, CA USA), 300nM each primer, and 200nM fluorogenic
probe. The amplification consisted of an initial heating at 951C for
10min, followed by 40 cycles at 951C for 15s and 601C for 45s. The
standard curve was generated by using serial dilutions of pFG140
plasmid DNA (Microbix Biosystems Inc., Ontario, Canada) in the
genomic liver DNA solution.
RESULTS
Systemic AdCMVLuc dissemination from tumours
To demonstrate the systemic dissemination of viral vectors,
AdCMVLuc suspension was infused into two murine tumour
models, 4T1 and B16.F10, respectively, and one human tumour
xenograft, IMR-23. Bleeding was observed in many tumours
immediately after the removal of infusion needle but the amount of
bleeding was much less than the infused volume (i.e. 50ml). At 24h
after infusion, strong bioluminescence, an indication of luciferase
expression, was observed in the liver and tumour in all animal
models (see Figure 1). The bioluminescence from the liver
indicated that AdCMVLuc had escaped from tumours in local
gene delivery, because luciferase is an exogenous and nonsecre-
table protein. It should be retained in transfected, viable cells.
Kinetics of adenovirus dissemination
The plasma from blood samples at different time points, both
during and after the intratumoral infusion of AdCMVEGFP,
contained the viral vectors that could transfect 293 cells in vitro
(see Figure 2A). Qualitatively, the amount of AdCMVEGFP in the
plasma reached the peak at the end of intratumoral infusion and
A BC
Bottom
view
Side
view
1.0
0.8
0.6
0.4
0.2
×
1
0
6
 
p
h
o
t
o
n
s
 
s
e
c
−
1
 
c
m
−
2
 
s
r
−
1
Figure 1 Typical images of luciferase distribution at 24h after AdCMVLuc infusion into different tumours: (A) 4T1 in a Balb/c mouse, (B) B16.F10 in a
C57BL/6 mouse, and (C) IMR-23 in a Balb/c nude mouse. The dose of infusion was 2.0 10
8pfutumour
 1.
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sthen decreased quickly with time. It was significantly lower than
the peak value at 10min and nearly undetectable at 2h after the
infusion. Cells from blood samples contained only a few
AdCMVEGFP that could transfect 293 cells in vitro (see
Figure 2B), indicating that the virus dissemination was not
mediated by transfected tumour or blood-borne cells. To our best
knowledge, this was the first direct evidence that demonstrated the
adenovirus dissemination during intratumoral infusion.
Role of tumour or blood-borne cells in virus dissemination
To further investigate the role of tumour or blood-borne cells in
virus dissemination, we performed two additional experiments.
Firstly, we infused luciferase-expressing cells into the tail vein of
mice, and observed that nearly all infused cells accumulated in the
lung (Figure 3). Secondly, we infused AdCMVEGFP vectors into
4T1 tumours and examined EGFP expression in the liver, tumour,
lung, and blood at 24h after the infusion. We observed EGFP
expression in liver and tumour tissues but could not detect EGFP-
expressing cells in the lung and blood (Figure 4). These results
confirmed it again that the virus dissemination was not mediated
by transfected tumour or blood-borne cells.
Quantitative measurement of adenoviruses in liver and
tumour tissues
To quantitatively understand the significance of systemic adeno-
virus dissemination at early time points, we quantified the copy
Infusion
was started
Infusion
was ended
t=0 25 s 50 s 5 min 10 min 2 h 24 h
Sampling time
A
B
Figure 2 EGFP expression in 293 cells transfected by AdCMVEGFP that was isolated from (A) the plasma and (B) the lysed blood cells in mice. The
blood samples were collected at different time points after the intratumoral infusion of AdCMVEGFP was started. The dose of infusion was
3.0 10
8pfutumour
 1. The infusion was performed at 1mls
 1 over a 50-s period.
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Figure 3 Typical images of luciferase distribution in three mice at (A) 10min and (B) 24h after intravenous injection of 4T1 cells expressing luciferase.
The dose of injection was 10
6 cells per mouse.
Whole blood
Liver Tumour
Lung
Figure 4 Typical images of EGFP distribution in different tissues at 24h
after the infusion of AdCMVEGFP into 4T1 tumours. Bar¼100mm. The
dose of infusion was 3.0 10
8pfutumour
 1.
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snumbers of adenoviruses in liver and tumour tissues at 10min
after the intratumoral infusion of AdCMVEGFP. We chose this
time point for three reasons. Firstly, data in the literature show
that adenoviruses have a plasma half-life of B2min (Worgall et al,
1997; Alemany et al, 2000b) (see also Figure 2A in this study).
Thus, approximately 97% of disseminated viruses have been
cleared from the blood at 10min. Secondly, the clearance in mice is
mainly through the liver (Herz and Gerard, 1993; Hackett et al,
2000). Finally, the amount of active adenoviral vectors in the liver
decreases with time (Worgall et al, 1997). As a result, the copy
numbers of adenoviruses in the liver at 10min after the infusion
provided the best estimate of the total amount of adenoviruses
disseminated from the tumour.
The ratio of the copy numbers of adenoviruses between liver and
tumour is shown in Figure 5. The minimal value was 0.2; eight out
of 10 mice had a ratio greater than 2; and four mice had a ratio
close to or greater than 10. These data demonstrated that a
significant amount of adenoviruses had disseminated from
tumours within 10min after the intratumoral infusion.
DISCUSSION
We observed the systemic virus dissemination in all three animal
models after intratumoral infusion of adenoviral vectors. In 4T1
tumours, the dissemination occurred mainly during the first
10min after the infusion was started. The amount of viruses
disseminated into the liver could be one order of magnitude higher
than that retained in the tumour. The blood and lung in mice
contained few transfected cells after the intratumoral infusion.
However, tumour cells injected intravenously into the mice
accumulated mainly in the lung. These observations in combina-
tion with data in the literature allowed us to determine the
mechanism of systemic virus dissemination during the first 24h
after the intratumoral infusion was started.
Potentially, the mechanisms of dissemination include cell-
mediated transport and diffusion and convection of viral vectors
from the interstitial space into the lumen of tumour microvessels.
We have showed previously that the diffusion process is too slow
to cause the virus dissemination after intratumoral infusion (Wang
et al, 2003). Based on diffusion, the maximum amount of
disseminated viruses would be several orders of magnitude less
than that retained in the tumour. This was inconsistent with the
observations shown in Figures 1, 2, 4 and 5 and data in the
literature (DeWeese et al, 2001; Nemunaitis et al, 2001; Sauthoff
et al, 2003). Therefore, diffusion is negligible during the virus
dissemination.
The cell-mediated transport was likely to be insignificant as well.
The reasons are as follows. First, the amount of adenoviral vectors
associated with cells in blood samples shown in Figure 2B was
extremely low compared with that in the plasma. Even the cell-
associated vectors could be originally in the plasma and then
nonspecifically bind to erythrocytes (Cichon et al, 2003) or be
co-precipitated with blood cells during the centrifuging process.
Second, most tumour cells injected intravenously accumulated in
the lung (Figure 3), which was consistent with data in the literature
that lung is the primary target of metastatic tumour cells in mice
(Lee, 1983). Third, few transfected cells existed in the blood and
lung at 24h after the intratumoral infusion (Figure 4). Therefore,
the observations shown in Figure 2B indicated that blood-borne
cells played an insignificant role in the virus dissemination, while
the observations shown in Figures 3 and 4 indicated that the virus
dissemination was not mediated by transfected tumour cells either.
Convection is in general negligible in the centre of solid
tumours, due to uniformly elevated interstitial fluid pressure and
intrinsic leakiness of tumour microvessels (Jain, 1997). Convection
is important only during the intratumoral infusion and the first
few minutes after the intratumoral infusion when a fluid pressure
gradient is created around the tip of the infusion needle. After the
infusion, the pressure gradient should decrease rapidly with time
since (a) the equilibrium time constant between the microvascular
pressure and the interstitial fluid pressure is approximately 10s
(Netti et al, 1995) and (b) the microvascular pressure in the
tumour should return to the undisturbed level within a few
minutes after the infusion, due to blood circulation. Therefore,
convection can only cause virus dissemination at early time points
but becomes insignificant at late time points.
Taken together, the virus dissemination occurred after the
adenoviral vectors entered the system circulation via infusion-
induced convective transport. The entrances were the leaky
microvessels that were either intrinsically hyperpermeable, with
pores in the microvessel wall being larger than adenoviruses
(Hobbs et al, 1998; Yuan, 1998) or damaged by the infusion
procedures. In the blood, adenoviruses were rapidly taken up by
Kupffer cells and hepatocytes in the liver, with a plasma half-life of
B2min (Alemany et al, 2000b). The dissemination of the
adenoviral vectors was significant only during the first few
minutes (o10min) after the intratumoral infusion.
The ratio of copy numbers of adenoviruses between liver and
tumour shown in Figure 5 had a large variation among different
animals. This result was qualitatively consistent with the ratio of
bioluminescence intensities between liver and tumour after
intratumoral infusion of AdCMVLuc (data not shown). Such
variations were unlikely to be caused by the experimental
procedures because the tip of the needle had been carefully placed
near the centre of all tumours and the infusion protocol had been
standardised by using a syringe pump. The variation could be due
to the heterogeneous distribution of microvessels, a hallmark of
solid tumours. As a result, the number of leaky microvessels
involved in virus dissemination would depend on vascularisation
and location of the needle tip in tumours.
Systemic virus dissemination after intratumoral infusion has
been investigated in previous studies (DeWeese et al, 2001;
Nemunaitis et al, 2001; Sauthoff et al, 2003). Sauthoff et al
(2003) have detected a self-replicating adenoviral vector in mouse
blood at 10min after intratumoral infusion, based on the assay of
virus titration on 293 cells. The number of viral DNA copies in the
blood is one order of magnitude lower than that retained in the
tumour and no adenoviruses can be detected in the liver during the
first week after the intratumoral infusion. The liver data are
inconsistent with those in the literature, which have demonstrated
that nearly 99% of adenoviruses in the systemic circulation will
eventually accumulate in the liver of mice (Herz and Gerard, 1993;
Hackett et al, 2000). This discrepancy is likely to be caused by the
inappropriate use of virus titration assay. It is well known that
most adenoviruses in the liver are internalised by Kupffer cells or
hepatocytes. The internalisation and the subsequent intracellular
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Figure 5 Ratio of virus copy numbers between liver and tumour at
10min after the infusion of AdCMVEGFP into 4T1 tumours implanted in
10 different mice.
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strafficking of adenoviruses may make these vectors lose their
ability to transfect 293 cells. Therefore, a better way to determine
the virus accumulation in the liver is to quantify the copy number
of unique viral DNA sequences as shown in this study. Sauthoff
et al (2003) have also shown that the adenoviral vectors can be
detected in the blood at 2–8 weeks after the intratumoral infusion,
presumably due to the replication of vectors in tumours. We used
nonreplicating vectors so that we did not observe virus
dissemination at late time points (Wang et al, 2003).
In a clinical study, the amount of adenoviral DNA in the blood at
30min after the intratumoral infusion has varied between 0.007 and
0.129% of that infused into tumours (DeWeese et al, 2001). The
amount of adenoviruses disseminated into the liver or other normal
tissues is not determined in patients. Based on the blood data alone,
one cannot estimate the amount of disseminated adenoviruses
because it is likely that most adenoviruses disseminated during the
intratumoral infusion have already been taken up by the liver at
30min (Alemany et al, 2000b) (see also Figures 2 and 5).
In summary, we demonstrated that the virus dissemination
occurred during the first few minutes after the intratumoral
infusion was started. It was due to infusion-induced convective
transport of viral vectors into leaky tumour microvessels. In future
studies, we will investigate effects of infusion rate and pressure as
well as structures of tumour tissues on virus dissemination. The
findings in this study suggest that it is desirable to develop
polymeric delivery systems that can increase the concentration of
adenoviruses in solid tumours and simultaneously reduce the
amount of disseminated adenoviruses in normal tissues, particu-
larly in the liver, thereby improving the efficacy/toxicity ratio in
cancer gene therapy.
ACKNOWLEDGEMENTS
We thank Drs David Zaharoff and Sheng Tong for the scientific
discussion, and Drs Jun Chen and Lori Setton for the help in PCR
experiment. This work is supported in part by grants from the
National Science Foundation (BES-9984062) and the National
Institutes of Health (CA81512).
REFERENCES
Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M,
Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg
A (2000) Use of transcriptional regulatory sequences of telomerase
(hTER and hTERT) for selective killing of cancer cells. Mol Ther 2:
539–544
Adachi Y, Reynolds PN, Yamamoto M, Wang M, Takayama K, Matsubara S,
Muramatsu T, Curiel DT (2001) A midkine promoter-based conditionally
replicative adenovirus for treatment of pediatric solid tumors and bone
marrow tumor purging. Cancer Res 61: 7882–7888
Alemany R, Balague C, Curiel DT (2000a) Replicative adenoviruses for
cancer therapy. Nat Biotechnol 18: 723–727
Alemany R, Suzuki K, Curiel DT (2000b) Blood clearance rates of
adenovirus type 5 in mice. J Gen Virol 81: 2605–2609
Alvarez RD, Curiel DT (1997) A phase I study of recombinant adenovirus
vector-mediated intraperitoneal delivery of herpes simplex virus
thymidine kinase (HSV-TK) gene and intravenous ganciclovir for
previously treated ovarian and extraovarian cancer patients. Hum Gene
Ther 8: 597–613
Anderson WF (1998) Human gene therapy. Nature 392: 25–30
Baranowski E, Ruiz-Jarabo CM, Domingo E (2001) Evolution of cell
recognition by viruses. Science 292: 1102–1105
Blackburn RV, Galoforo SS, Corry PM, Lee YJ (1998) Adenoviral-mediated
transfer of a heat-inducible double suicide gene into prostate carcinoma
cells. Cancer Res 58: 1358–1362
Bowers WJ, Olschowka JA, Federoff HJ (2003) Immune responses to
replication-defective HSV-1 type vectors within the CNS: implications for
gene therapy. Gene Ther 10: 941–945
Bramson JL, Hitt M, Gauldie J, Graham FL (1997) Pre-existing immunity to
adenovirus does not prevent tumor regression following intratumoral
administration of a vector expressing IL-12 but inhibits virus
dissemination. Gene Ther 4: 1069–1076
Brown BD, Lillicrap D (2002) Dangerous liaisons: the role of
‘danger’ signals in the immune response to gene therapy. Blood 100:
1133–1140
Chada S, Ramesh R, Mhashilkar AM (2003) Cytokine- and chemokine-
based gene therapy for cancer. Curr Opin Mol Ther 5: 463–474
Chen D, Murphy B, Sung R, Bromberg JS (2003) Adaptive and innate
immune responses to gene transfer vectors: role of cytokines and
chemokines in vector function. Gene Ther 10: 991–998
Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB
(1999) Use of L-plastin promoter to develop an adenoviral system that
confers transgene expression in ovarian cancer cells but not in normal
mesothelial cells. Cancer Gene Ther 6: 99–106
Cichon G, Boeckh-Herwig S, Kuemin D, Hoffmann C, Schmidt HH, Wehnes
E, Haensch W, Schneider U, Eckhardt U, Burger R, Pring-Akerblom P
(2003) Titer determination of Ad5 in blood: a cautionary note. Gene Ther
10: 1012–1017
Crystal RG (1995) Transfer of genes to humans: early lessons and obstacles
to success. Science 270: 404–410
DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper
U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi
S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW
(2001) A phase I trial of CV706, a replication-competent, PSA selective
oncolytic adenovirus, for the treatment of locally recurrent prostate
cancer following radiation therapy. Cancer Res 61: 7464–7472
Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT
(1996) Targeted gene delivery by tropism-modified adenoviral vectors.
Nat Biotechnol 14: 1574–1578
Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS,
Moolten FL, Abraham GN (1993) The ‘bystander effect’: tumor
regression when a fraction of the tumor mass is genetically modified.
Cancer Res 53: 5274–5283
Garver Jr RI, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT (1994)
Strategy for achieving selective killing of carcinomas. Gene Ther 1: 46–50
Gossen M, Bujard H (1992) Tight control of gene expression in mammalian
cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:
5547–5551
Graham FL, Prevec L (1995) Methods for construction of adenovirus
vectors. Mol Biotechnol 3: 207–220
Hackett NR, El Sawy T, Lee LY, Silva I, O’Leary J, Rosengart TK, Crystal RG
(2000) Use of quantitative TaqMan real-time PCR to track the time-
dependent distribution of gene transfer vectors in vivo. Mol Ther 2: 649–
656
Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA, Anderson
WF (1997) Targeting retroviral vectors to vascular lesions by genetic
engineering of the MoMLV gp70 envelope protein. Hum Gene Ther 8:
2183–2192
Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN,
Toledano A, Hellman S, Kufe DW, Weichselbaum RR (1995) Spatial and
temporal control of gene therapy using ionizing radiation. Nat Med 1:
786–791
Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR (1994) Gene
therapy for cancer using tumour-specific prodrug activation. Gene Ther
1: 170–175
Herz J, Gerard RD (1993) Adenovirus-mediated transfer of low density
lipoprotein receptor gene acutely accelerates cholesterol clearance in
normal mice. Proc Natl Acad Sci USA 90: 2812–2816
Hobbs SK, Monsky W, Yuan F, Roberts WG, Griffith L, Torchillin VP, Jain
RK (1998) Regulation of transport pathways in tumor vessels: role of
tumor type and microenvironment. Proc Nat Acad Sci USA 95: 4607–
4612
Huang Q, Hu JK, Lohr F, Zhang L, Braun R, Lanzen J, Little JB, Dewhirst
MW, Li CY (2000) Heat-induced gene expression as a novel targeted
cancer gene therapy strategy. Cancer Res 60: 3435–3439
Systemic dissemination of viral vectors in gene delivery
Y Wang et al
1419
British Journal of Cancer (2005) 92(8), 1414–1420 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sJaggar RT, Chan HY, Harris AL, Bicknell R (1997) Endothelial cell-specific
expression of tumor necrosis factor-alpha from the KDR or E-selectin
promoters following retroviral delivery. Hum Gene Ther 8: 2239–2247
Jain RK (1997) Delivery of molecular and cellular medicine to solid tumors.
Microcirculation 4: 1–23
Jenster G, Spencer TE, Burcin MM, Tsai SY, Tsai MJ, O’Malley BW (1997)
Steroid receptor induction of gene transcription: a two-step model. Proc
Natl Acad Sci USA 94: 7879–7884
Jooss K, Chirmule N (2003) Immunity to adenovirus and adeno-associated
viral vectors: implications for gene therapy. Gene Ther 10: 955–963
Koshikawa N, Takenaga K, Tagawa M, Sakiyama S (2000) Therapeutic
efficacy of the suicide gene driven by the promoter of vascular
endothelial growth factor gene against hypoxic tumor cells. Cancer Res
60: 2936–2941
Kumagai T, Tanio Y, Osaki T, Hosoe S, Tachibana I, Ueno K, Kijima T,
Horai T, Kishimoto T (1996) Eradication of Myc-overexpressing small
cell lung cancer cells transfected with herpes simplex virus thymidine
kinase gene containing Myc-Max response elements. Cancer Res 56:
354–358
Ledley FD (1996) Pharmaceutical approach to somatic gene therapy. Pharm
Res 13: 1595–1614
Lee YT (1983) Breast carcinoma: pattern of metastasis at autopsy. J Surg
Oncol 23: 175–180
Lohr F, Huang Q, Hu K, Dewhirst MW, Li CY (2001) Systemic vector
leakage and transgene expression by intratumorally injected recombi-
nant adenovirus vectors. Clin Cancer Res 7: 3625–3628
Lowenstein PR (2003) Virology and immunology of gene therapy, or
virology and immunology of high MOI infection with defective viruses.
Gene Ther 10: 933–934
Lu Y, Carraher J, Zhang Y, Armstrong J, Lerner J, Rogers WP, Steiner MS
(1999) Delivery of adenoviral vectors to the prostate for gene therapy.
Cancer Gene Ther 6: 64–72
Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA,
Shimura S, Yang G, Timme TL, Thompson TC (1999) Adenovirus-
mediated interleukin-12 gene therapy for prostate cancer: suppression of
orthotopic tumor growth and pre-established lung metastases in an
orthotopic model. Gene Ther 6: 338–349
Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J,
McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D
(2001) Phase II trial of intratumoral administration of ONYX-015, a
replication-selective adenovirus, in patients with refractory head and
neck cancer. J Clin Oncol 19: 289–298
Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK (1995) Time-dependent
behavior of interstitial fluid pressure in solid tumors: implications for
drug delivery. Cancer Res 55: 5451–5458
Paielli DL, Wing MS, Rogulski KR, Gilbert JD, Kolozsvary A, Kim JH,
Hughes J, Schnell M, Thompson T, Freytag SO (2000) Evaluation of the
biodistribution, persistence, toxicity, and potential of germ-line trans-
mission of a replication-competent human adenovirus following
intraprostatic administration in the mouse. Mol Ther 1: 263–274
Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, Clackson T
(2000) Delivery of a stringent dimerizer-regulated gene ex-
pression system in a single retroviral vector. Proc Natl Acad Sci USA
97: 13221–13226
Pope IM, Poston GJ, Kinsella AR (1997) The role of the bystander effect in
suicide gene therapy. Eur J Cancer 33: 1005–1016
Rosenfeld ME, Feng M, Michael SI, Siegal GP, Alvarez RD, Curiel DT (1995)
Adenoviral-mediated delivery of the herpes simplex virus thymidine
kinase gene selectively sensitizes human ovarian carcinoma cells to
ganciclovir. Clin Cancer Res 1: 1571–1580
Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, Yee H, Pipiya T,
Rom WN, Hay JG (2003) Intratumoral spread of wild-type adenovirus
is limited after local injection of human xenograft tumors: virus
persists and spreads systemically at late time points. Hum Gene Ther
14: 425–433
Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ (2000) Glucose
deprivation-induced oxidative stress in human tumor cells. A funda-
mental defect in metabolism? Ann N Y Acad Sci 899: 349–362
Tjuvajev JG, Chen SH, Joshi A, Joshi R, Guo ZS, Balatoni J, Ballon D,
Koutcher J, Finn R, Woo SL, Blasberg RG (1999) Imaging adenoviral-
mediated herpes virus thymidine kinase gene transfer and expression in
vivo. Cancer Res 59: 5186–5193
Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K,
Drake T, Belldegrun A, Glaspy J, Economou JS (1996) In vivo cancer gene
therapy with a recombinant interleukin-2 adenovirus vector. Cancer
Gene Ther 3: 11–17
UKCCCR (1998) United Kingdom Co-ordinating Committee on Cancer
Research (UKCCCR) guidelines for the welfare of animals in experi-
mental neoplasia (second edition). Br J Cancer 77: 1–10
Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient
supply, and metabolic microenvironment of human tumors: a review.
Cancer Res 49: 6449–6465
Wang Y, Hu JK, Krol A, Li YP, Li CY, Yuan F (2003) Systemic
dissemination of viral vectors during intratumoral injection. Mol Cancer
Ther 2: 1233–1242
Worgall S, Wolff G, Falck-Pedersen E, Crystal RG (1997) Innate immune
mechanisms dominate elimination of adenoviral vectors following in
vivo administration. Hum Gene Ther 8: 37–44
Yuan F (1998) Transvascular drug delivery in solid tumors. Semin Radiat
Oncol 8: 164–175
Systemic dissemination of viral vectors in gene delivery
Y Wang et al
1420
British Journal of Cancer (2005) 92(8), 1414–1420 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s